Lateral Flow Immunoassay for Functional C1-INH Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for measuring functional C1-esterase inhibitor (C1-INH) levels in hereditary angioedema (HAE) are limited by high false positives and low negative predictive value, necessitating the development of more accurate and rapid diagnostic methods.
Innovation Solution
A lateral flow immunoassay (LFA) device and method for detecting and quantifying functional C1-esterase inhibitor (fC1-INH) using a conjugate pad with specific agents immobilized on zones, allowing for rapid and cost-effective detection in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If chromogenic assay or complex ELISA method is used to measure C1-INH functional level, then measurement capability is achieved, but false positives occur and negative predictive value is low (62%)
Solution Approach 1:
The assay is divided into two independent measurement systems: (1) C1-INH functional activity measurement using C1s and C4, and (2) total C1-INH concentration measurement using anti-C1-INH antibody. By segmenting the measurement into functional activity and total concentration components, the assay can distinguish between functional deficiency and non-functional variants, thereby reducing false positives and improving negative predictive value
Solution Approach 2:
The invention introduces C4 as an intermediary substance to indirectly measure C1-INH functional activity. Instead of directly measuring C1-INH function, the assay measures C4 consumption (which occurs when C1-INH is functional and inhibits C1s), providing a more reliable indirect indicator of functional status that reduces false positives
2Measurement precision
If chromogenic assay or complex ELISA method is used, then C1-INH measurement is achieved, but the procedure is complex and time-consuming
Solution Approach 1:
The invention merges multiple measurement capabilities into a single lateral flow device platform. Both functional activity measurement (using C1s-C4-C1-INH interaction) and total concentration measurement (using anti-C1-INH antibody) are integrated into one device, eliminating the need for separate complex ELISA procedures and reducing overall assay complexity
Solution Approach 2:
The invention replaces complex mechanical/chemical ELISA procedures with a lateral flow immunoassay system. The lateral flow mechanism uses capillary action and simple antigen-antibody binding on a membrane strip, substituting complex multi-step ELISA protocols with a simpler, faster, and equally precise measurement system
3Measurement precision
If conventional ELISA method is used, then measurement is achieved, but the time required is excessive and cost is high
Solution Approach 1:
The lateral flow device is pre-prepared with all necessary reagents immobilized on the membrane strip during manufacturing. C1s, C4, anti-C1-INH antibody, and control antibodies are pre-positioned in specific zones, eliminating the need for time-consuming reagent preparation and incubation steps required in conventional ELISA, thereby significantly reducing assay time while maintaining precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LFA device provides rapid, sensitive, and cost-effective detection of fC1-INH levels, improving diagnostic accuracy and expanding screening for HAE, with potential for monitoring disease progression and therapeutic response.
Implementation Method 1
a first agent and a second agent are immobilized, respectively, on which a first agent and a second agent are immobilized... The first agent can be a functional C1 inhibitor (fC1-INH) binding agent or a C1 inhibitor (C1-INH) binding agent
Data Source
AI summary
A device for detecting and/or quantifying functional C1-esterase inhibitor (fC1-INH), the device comprising: (i) a conjugate pad comprising a first zone and a second zone, on which a first agent and a second agent are immobilized, respectively, and (ii) a membrane, which is in communication with the conjugate pad, wherein the membrane comprises a third zone, on which a third agent is immobilized. The conjugate pad may further comprise a fourth zone for placing a biological sample, which flows through the device in the order of the first zone, the second zone, and the third zone.